Bayer

Contact Us

Congress Library

American Heart Association Scientific Sessions 2025

Presentations

 

Mineralocorticoid Receptor Antagonists and Race in Heart Failure - An Individual Participant Data Meta-Analysis of Randomized Trials Mineralocorticoid Receptor Antagonists and Race in Heart Failure - An Individual Participant Data Meta-Analysis of Randomized Trials

Jawad Butt

Mineralocorticoid Receptor Antagonists and Race in Heart Failure - An Individual Participant Data Meta-Analysis of Randomized Trials

Click to access
Efficacy of Finerenone in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pre-specified Analysis of Heart Rate in the FINEARTS-HF Trial Efficacy of Finerenone in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pre-specified Analysis of Heart Rate in the FINEARTS-HF Trial

Misato Chimura

Efficacy of Finerenone in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction: A Pre-specified Analysis of Heart Rate in the FINEARTS-HF Trial

Click to access
Effects of Finerenone on Individual Components of the Kansas City Cardiomyopathy Questionnaire in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Effects of Finerenone on Individual Components of the Kansas City Cardiomyopathy Questionnaire in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Yasuhiro Hamatani

Effects of Finerenone on Individual Components of the Kansas City Cardiomyopathy Questionnaire in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Click to access
The HFpEF-ABA Score, Incident Heart Failure, and Finerenone Across the Spectrum of Cardiovascular-Kidney-Metabolic Risk The HFpEF-ABA Score, Incident Heart Failure, and Finerenone Across the Spectrum of Cardiovascular-Kidney-Metabolic Risk

Riccardo Inciardi

The HFpEF-ABA Score, Incident Heart Failure, and Finerenone Across the Spectrum of Cardiovascular-Kidney-Metabolic Risk

Click to access
Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

John Ostrominski

Effects of Finerenone on Heart Failure Outcomes According to Baseline Heart Failure Risk in Chronic Kidney Disease and Type 2 Diabetes

Click to access
Estimated Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Patients with Chronic Kidney Disease and Type 2 Diabetes Estimated Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Patients with Chronic Kidney Disease and Type 2 Diabetes

John Ostrominski

Estimated Lifetime Benefits of Finerenone on Cardiorenal Morbidity and Mortality in Patients with Chronic Kidney Disease and Type 2 Diabetes

Click to access
Interplay Between Heart Failure Events, New-Onset Diabetes, and Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction Interplay Between Heart Failure Events, New-Onset Diabetes, and Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

John Ostrominski

Interplay Between Heart Failure Events, New-Onset Diabetes, and Finerenone in Heart Failure with Mildly Reduced or Preserved Ejection Fraction

Click to access
Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes

John Ostrominski

Timing of Cardiovascular and Kidney Benefits with Finerenone in Heart Failure and Chronic Kidney Disease with Type 2 Diabetes

Click to access
Finerenone Reduces Sudden Death Across the Spectrum of Cardio-Kidney-Metabolism - The FINE-HEART Pooled Analysis Finerenone Reduces Sudden Death Across the Spectrum of Cardio-Kidney-Metabolism - The FINE-HEART Pooled Analysis

Maria Pabon

Finerenone Reduces Sudden Death Across the Spectrum of Cardio-Kidney-Metabolism - The FINE-HEART Pooled Analysis

Click to access
Major Adverse Cardiovascular Events across the Spectrum of Cardio-Kidney-Metabolic Syndrome - A FINE-HEART Pooled Analysis Major Adverse Cardiovascular Events across the Spectrum of Cardio-Kidney-Metabolic Syndrome - A FINE-HEART Pooled Analysis

Maria Pabon

Major Adverse Cardiovascular Events across the Spectrum of Cardio-Kidney-Metabolic Syndrome - A FINE-HEART Pooled Analysis

Click to access
Finerenone Reduces Loop Diuretic Requirement in Patients with Type 2 Diabetes and CKD - A Participant Level Pooled Analysis of FIDELIO-DKD and FIGARO-DKD Finerenone Reduces Loop Diuretic Requirement in Patients with Type 2 Diabetes and CKD - A Participant Level Pooled Analysis of FIDELIO-DKD and FIGARO-DKD

Muthiah Vaduganathan

Finerenone Reduces Loop Diuretic Requirement in Patients with Type 2 Diabetes and CKD - A Participant Level Pooled Analysis of FIDELIO-DKD and FIGARO-DKD

Click to access
Finerenone and Liver Fibrosis Assessed by Fibrosis-4 (FIB-4) Index in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction - Results from the FINEARTS-HF Trial Finerenone and Liver Fibrosis Assessed by Fibrosis-4 (FIB-4) Index in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction - Results from the FINEARTS-HF Trial

Mingming Yang

Finerenone and Liver Fibrosis Assessed by Fibrosis-4 (FIB-4) Index in Patients with Heart Failure and Mildly Reduced or Preserved Ejection Fraction - Results from the FINEARTS-HF Trial

Click to access

Follow Us

You are encouraged to report side effects or quality complaints of products to the FDA by visiting www.fda.gov/medwatch or calling 1-800-FDA-1088. For Bayer products, you can report these directly to Bayer by clicking here.

 

This site provides access to balanced and evidence-based medical information related to our therapeutic areas of focus and is intended to serve as a medical resource for US HCPs. This may include investigational compounds or investigational new uses of FDA-approved Bayer products. The information provided is not intended to be promotional or provide medical advice. Please refer to the full Prescribing Information for approved indications, contraindications, warnings and precautions, and adverse events.

Copyright © 2025 Bayer

Bayer and the Bayer Cross are registered trademarks of Bayer.

sitemap